Could a migraine drug stop cluster headaches? small study hints at hope
NCT ID NCT05264714
First seen Jan 12, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This pilot study tested whether rimegepant (Nurtec ODT), a drug already used for migraines, could help prevent cluster headaches. Twenty adults with recurrent cluster headaches took the drug every other day for a week. Researchers measured changes in weekly attack frequency and pain severity to see if it might be a useful preventive option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLUSTER HEADACHE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rimegepant (Nurtec ODT)
What this could lead to
If it works, this could point toward a new preventive treatment for cluster headaches, reducing attack frequency.
What could go wrong
This is a very small pilot study with only 20 people, so results may not apply to everyone. It's early-stage and may not show clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.